| Name | Title | Contact Details |
|---|
Since 1902, BIA is recognized by its customers for the quality of its products and services in the mining and quarrying, construction, transport and energy sectors as exclusive distributor of Komatsu equipment and parts, as well as other reputable manufacturers like Metso, Cummins, Bomag, MAN, Foton, Furukawa, GHH… for complementary products. Today BIA Group has become a well-established, multinational and trusted long-term business partner, operating in more than 20 countries in Africa and in the Benelux regions. The family-owned group distinguishes itself through the extent of its network and state-of-the-art technical facilities to support its clients close to their operations. The group is continuously developing its capabilities and expertise to meet the ever-growing customer needs. BIA provides a wide range of solutions including equipment sales, rental, parts supply, aftersales services as well as support services such as structured financing solutions, supply chain management and training to assist its customers on their projects development. More recently, BIA was pioneer in adopting innovation & technology solutions to increase customers productivity and safety on sites.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
We provide seamless, hands-on management and strategic guidance to help you unlock the full potential of your Pendo investment. From setup to optimization, our team ensures cleaner data, stronger engagement, and measurable results for your business.